Cell therapy

Nexcella Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

Retrieved on: 
Thursday, May 4, 2023
Hematopoietic stem cell transplantation, Gene, Cell therapy, AL amyloidosis, Hadassah Medical Center, Amyloidosis, Cell, Society, Immunotherapy

LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq: IMMX) (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.

Key Points: 
  • LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq: IMMX) (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.
  • “We are delighted to present additional clinical data for what we believe is the only CAR-T in development in AL Amyloidosis at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator for the NEXICART-1 Phase 1b/2a clinical trial of NXC-201.
  • “A potential one-time treatment such as CAR-T NXC-201 in AL amyloidosis would be a welcome option for this devastating disease.”
    Event: 26th Annual Meeting of The American Society of Gene and Cell Therapy, Los Angeles, CA

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

Retrieved on: 
Thursday, May 4, 2023
Hematopoietic stem cell transplantation, Gene, Cell therapy, AL amyloidosis, Hadassah Medical Center, Amyloidosis, Cell, Society, Immunotherapy

LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.

Key Points: 
  • LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.
  • “We are delighted to present additional clinical data for what we believe is the only CAR-T in development in AL Amyloidosis at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator for the NEXICART-1 Phase 1b/2a clinical trial of NXC-201.
  • “A potential one-time treatment such as CAR-T NXC-201 in AL amyloidosis would be a welcome option for this devastating disease.”
    Event: 26th Annual Meeting of The American Society of Gene and Cell Therapy, Los Angeles, CA

Empowering R&D in Special Diseases, "Next Generation" CRO Company TriApex Completes Series C with Hundreds of Millions of CNY, Led by Legend Capital

Retrieved on: 
Thursday, May 4, 2023
DSM-IV codes, Laboratory, Central nervous system, CGT, Gene, Cell therapy, Quality of life, Research, CNS, Certification, Ophthalmology, AAALAC, Legend Holdings, Drug discovery, Ecosystem, Pharmaceutical industry, Fine chemical

HONG KONG, May 4, 2023 - (ACN Newswire) - TriApex Laboratories Co., Ltd (hereinafter referred to as "TriApex") recently announced the completion of its Series C financing round, which was led by Legend Capital.

Key Points: 
  • HONG KONG, May 4, 2023 - (ACN Newswire) - TriApex Laboratories Co., Ltd (hereinafter referred to as "TriApex") recently announced the completion of its Series C financing round, which was led by Legend Capital.
  • TriApex's customers include many leading pharmaceutical and biotech companies located in China, Europe, and the US.
  • TriApex has a professional and dedicated team with lofty career pursuits and is committed to providing high-quality service.
  • We look forward to TriApex becoming a next-generation CRO service organization with global influence in future development."

Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy

Retrieved on: 
Monday, May 1, 2023
CELU, Gene, Cell therapy, Instituto de Biologia Molecular e Celular, Cell, Regenerative medicine, Patient, Society, Pharmaceutical industry

FLORHAM PARK, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’s Chief Medical Officer, will present data at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy, which will be held May 16-20th in Los Angeles.

Key Points: 
  • FLORHAM PARK, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’s Chief Medical Officer, will present data at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy, which will be held May 16-20th in Los Angeles.
  • “We have had a long interest in the role of cell therapy in autoimmune diseases and look forward to presenting our MLASC data in Crohn’s disease at the upcoming ASGCT annual meeting,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder.
  • We believe this cell therapy candidate could make a significant difference as a therapeutic option for patients.
  • We’re moving forward with confidence regarding the potential therapeutic benefits of MLASCs as we advance the development of therapeutic options for patients,” said Hariri.

Gilead Sciences Announces First Quarter 2023 Financial Results

Retrieved on: 
Thursday, April 27, 2023
Oncology, AIDS, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Table, IRAK4, Lenacapavir, GAAP, Earnings per share, Immunomedics, Acquisition, Investment, Patient, TS, Infection, Rheumatoid arthritis, Acute lymphoblastic leukemia, Obeldesivir, Liver disease, Impact of the COVID-19 pandemic on hospitals, Research, European Congress of Mathematics, B-cell lymphoma, FTC, Growth, Immunodeficiency, FDA, Conference, IPR, Cell therapy, COVID-19, ETR, CAR, CROI, European, Tax rate, Mortality, Inflammation, Omicron, HIV, Fungal infection, Kidney, Science, EPS, Society, Breast cancer, Pharmaceutical industry, Video game, Arms industry, Vaccine, Fine chemical, Bank, Sacituzumab govitecan, Remdesivir, Brexucabtagene autoleucel

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.
  • During the first quarter of 2023, Gilead generated $1.7 billion in operating cash flow.
  • During the first quarter of 2023, Gilead paid dividends of $969 million and repurchased $400 million of common stock.
  • First Quarter 2023 Product Gross Margin, Operating Expenses and Effective Tax Rate
    Product gross margin was 77.8% for the first quarter of 2023 compared to 78.2% for the same period in 2022.

Turn Biotechnologies Sharpens Immunology Focus by Adding Two Cell Therapy Specialists to its Medical Advisory Board

Retrieved on: 
Thursday, April 13, 2023
GMP, Business development, ASH, ISCT, Pediatrics, Cell therapy, Cancer, Howard Hughes Medical Institute, DRS, Research, ASPHO, Biomarker, Immunotherapy, Messenger, Transplant, Organization, MDS, Malignancy, Aplastic anemia, CAR, National Cancer Institute, American Society of Pediatric Hematology/Oncology, Patient, Physician, Memorial Sloan Kettering Cancer Center, Cell, IEC, MSK, Immunodeficiency, Committee on Finance, Epigenetics, Society, International Society, Primary immunodeficiency, Pharmaceutical industry, Nursing, Vaccine, Dentistry, Ageing, MD

MOUNTAIN VIEW, Calif., April 13, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, announced the appointment of two preeminent physicians to the company's Medical Advisory Board.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 13, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, announced the appointment of two preeminent physicians to the company's Medical Advisory Board.
  • Their expertise will help Turn Bio expand research and development to use the company's Epigenetic Reprogramming of Aging (ERA™) technology to increase the efficacy of immunotherapies.
  • Curran and Oved as our founding immunology medical advisors," said Anja Krammer, Turn Bio CEO.
  • He serves as Immune Effector Cell (IEC) Program Director and currently is the interim co-director of the Cell Therapy and Cell Engineering Facility (CTCEF), MSK's GMP investigational cell therapy facility.

Indee Labs Announces Strategic Investment from BroadOak BioTools Venture Fund

Retrieved on: 
Wednesday, April 12, 2023
Broad, Operating partner, West Pharmaceutical Services, DNA, Partnership, Innova Capital Partners, Cell therapy, Research, Dicarboxylic acid, Medicine, Cell, Labs, Fine chemical, Pharmaceutical industry, Vaccine, Indee Gold Mine

BERKELEY, Calif., April 12, 2023 /PRNewswire/ -- Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery, is partnering with BroadOak Capital Partners, a leading direct investment and advisory firm focused on life science research tools, pharmaceutical services and diagnostics, and DeciBio Consulting, a boutique life science strategy consulting firm to complete the development and launch of Hydropore RUO.

Key Points: 
  • Indee Labs to complete the development and launch of Hydropore RUO and Cell Therapy along with a direct DNA knock-in kit, enabled by BroadOak's strategic investment and domain expertise.
  • Indee Labs to launch Hydropore RUO and Cell Therapy, enabled by BroadOak's strategic investment and domain expertise.
  • "We are excited that our first investment of the BroadOak BioTools Venture Fund will support a leading technology that will unlock the potential of this transformative modality."
  • BroadOak's BioTools Venture Fund combines BroadOak's and DeciBio's deep technical expertise, sector-specific focus, and extensive network to support companies enabling the precision medicine and gene-therapy revolution.

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy

Retrieved on: 
Tuesday, April 11, 2023
Lymphoma, Amgen, Partnership, University, Genetic engineering, Doctor of Philosophy, Stanford University, Cell therapy, Multiple myeloma, Roche, Cancer, Multiple sclerosis, McKinsey & Company, Regenerative medicine, Novartis, Patient, SAN, University of California, Berkeley, Rare, Chemical engineering, Therapy, Biochemical engineering, Pharmaceutical industry

SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.

Key Points: 
  • SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.
  • "Kristin brings extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy to Poseida, and I am excited to welcome her to our leadership team," said Mark Gergen, Chief Executive Officer of Poseida.
  • Alongside our outstanding team, she will lead the execution of drug development programs in cell therapy, including our collaboration with Roche.
  • I look forward to working with Kristin as we continue to focus on redefining cell and gene therapy for patients in need."

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

Retrieved on: 
Wednesday, March 29, 2023
BCDA, DSMB, New Drug Application, Survival, Bone marrow, Allotransplantation, SAP, NK1R, Data monitoring committee, Medicare, Patient, Data, Substance P, American College, Therapy, Heart failure, Facial muscles, MSC, Bluerock Wildland Provincial Park, Security (finance), Myocardial injury after non-cardiac surgery, FDA, IND, III, Safety, Medical device, Centers for Medicare & Medicaid Services, Echocardiography, Cell therapy, Pharmaceuticals and Medical Devices Agency, Cell, Transplant, Research, CE, Quality of life, Form 10-K, COVID, Inflammation, Publication, Annual report, Pharmaceutical industry, Cryptocurrency, Helix, Heart

The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • This year holds the potential for catalysts that could dramatically improve our prospects, timetable, and attractiveness as a business.
  • Following the review, the DSMB indicated that it had no significant safety concerns and recommended that the study continue as designed.
  • After working with distinguished physician leaders, BioCardia expects to complete its formal submission for Japanese approval in the second quarter of 2023.

Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer

Retrieved on: 
Monday, March 20, 2023
Columbia University, PTC Therapeutics, Drug development, Duchenne muscular dystrophy, University, Gene, Cell therapy, PTC, Gene editing, CMO, RNA, Sympathetic nervous system, Duchenne, Marketing, Human genetics, American Society of Human Genetics, Genetics, Publication, Patient, Ophthalmology, MAA, Rare, European Society for Primary Immunodeficiencies, Amicus Therapeutics, FDA, Therapy, Fabry disease, IND, Society, DSM-IV codes, Disease, Pharmaceutical industry, Medical device, EU, Ascidiacea, Merck

BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics , a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics , a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO).
  • "Jay's deep knowledge and experience in gene therapy and complex indications will make an immense impact for patients and for Ascidian, as we advance our exon editing therapies addressing the underlying causes of disease," said Romesh Subramanian, Ph.D., President and Chief Executive Officer of Ascidian Therapeutics.
  • We're thrilled to welcome Jay to Ascidian."
  • Immediately prior to joining Ascidian, Dr. Barth served as CMO for Lexeo Therapeutics, a clinical-stage gene therapy company focused on addressing cardiovascular and central nervous system diseases.